Education
About Us
Working with TipRanks
Follow Us
Spectral Ai, Inc. Class A (MDAI)
:MDAI
MDAI Stock Chart & Stats
$1.43
-$0.15(-6.16%)
At close: 4:00 PM EST
$1.43
-$0.15(-6.16%)
Day’s Range― - ―
52-Week Range$1.04 - $3.25
Previous CloseN/A
Volume689.87K
Average Volume (3M)541.41K
Market Cap
$46.34M
Enterprise Value$59.18M
Total Cash (Recent Filing)$10.49M
Total Debt (Recent Filing)$9.66M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Apr 01, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding30,688,894
10 Day Avg. Volume339,515
30 Day Avg. Volume541,410
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-7.00
Price to Sales (P/S)1.72
P/FCF Ratio-5.52
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue2.55
Enterprise Value/Gross Profit5.68
Enterprise Value/Ebitda-4.64
Forecast
1Y Price Target
$4.50Price Target Upside214.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$20.15M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMDAI reported revenue of $5.1M above estimates, indicating strong performance.
Regulatory ApprovalsMDAI submitted regulatory filings to the FDA for the Burn indication with US De Novo FDA clearance expected in the first half of next year.
Revenue PotentialMDAI unlocks significant revenue from BARDA upon clearance and has additional debt available as needed.
Bears Say
Earnings MissFor 2Q25, the company reported revenues of $5.1M and a net loss of $0.31 per diluted share, compared to consensus estimates revenues of $5.5M and a net loss of $0.07.
Guidance ReductionManagement lowered FY25 BARDA revenue guidance to ~$18.5M due to the timing of work and the government shutdown.
Revenue ShortfallMDAI reported revenue of $3.8M, which was below estimates of $5.0M.
Spectral AI News
MDAI FAQ
What was Spectral Ai, Inc. Class A’s price range in the past 12 months?
Spectral Ai, Inc. Class A lowest stock price was $1.04 and its highest was $3.25 in the past 12 months.
What is Spectral Ai, Inc. Class A’s market cap?
Spectral Ai, Inc. Class A’s market cap is $46.34M.
When is Spectral Ai, Inc. Class A’s upcoming earnings report date?
Spectral Ai, Inc. Class A’s upcoming earnings report date is Apr 01, 2026 which is in 119 days.
How were Spectral Ai, Inc. Class A’s earnings last quarter?
Spectral Ai, Inc. Class A released its earnings results on Nov 11, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.105 by -$0.025.
Is Spectral Ai, Inc. Class A overvalued?
According to Wall Street analysts Spectral Ai, Inc. Class A’s price is currently Undervalued.
Does Spectral Ai, Inc. Class A pay dividends?
Spectral Ai, Inc. Class A does not currently pay dividends.
What is Spectral Ai, Inc. Class A’s EPS estimate?
Spectral Ai, Inc. Class A’s EPS estimate is -0.13.
How many shares outstanding does Spectral Ai, Inc. Class A have?
Spectral Ai, Inc. Class A has 30,688,894 shares outstanding.
What happened to Spectral Ai, Inc. Class A’s price movement after its last earnings report?
Spectral Ai, Inc. Class A reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.105. Following the earnings report the stock price went down -6.977%.
Which hedge fund is a major shareholder of Spectral Ai, Inc. Class A?
Currently, no hedge funds are holding shares in MDAI
Spectral AI Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (214.69% Upside)
$4.50 (214.69% Upside)
Hedge Fund Trend
Decreased
By 100.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.87%
Trailing 12-Months
Company Description
Spectral Ai, Inc. Class A
Spectral AI, Inc. (MDAI) is a technology-driven company specializing in the development of artificial intelligence (AI) solutions for the medical industry. The company's core product, the DeepView Wound Imaging System, leverages AI to provide healthcare professionals with real-time insights into wound healing and treatment efficacy, primarily focusing on burn and diabetic foot ulcers. Spectral AI aims to enhance patient outcomes and streamline clinical decision-making processes through cutting-edge imaging technology.
MDAI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. On the positive side, Spectral AI maintains a strong cash position and has made significant progress with its FDA submission, receiving positive international feedback for its DeepView system. However, the company faces challenges with declining research and development revenue, an increased net loss, and reduced revenue guidance for 2025. While the company is optimistic about its commercialization efforts and future growth, the current financial performance reflects some hurdles that need to be addressed.View all MDAI earnings summariesMDAI Stock 12 Month Forecast
Average Price Target
$4.50
▲(214.69% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
8.85% Insiders
3.09% Mutual Funds
4.42% Other Institutional Investors
81.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---